Bexxar
Showing 1 - 25 of 40
Multiple Myeloma Trial in Ann Arbor (Iodine I 131 Tositumomab)
Active, not recruiting
- Multiple Myeloma
- Iodine I 131 Tositumomab
-
Ann Arbor, MichiganUniversity of Michigan
Mar 16, 2022
Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Non-Hodgkin Trial in United States (Autologous transplantation
Completed
- Lymphoma, B-Cell
- +2 more
- Autologous transplantation using rituxan/BEAM
- Autologous transplantation using Bexxar/BEAM
-
New Haven, Connecticut
- +35 more
Oct 21, 2021
Mantle Cell Lymphoma Trial in United States (R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.)
Active, not recruiting
- Mantle Cell Lymphoma
- R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
-
Basking Ridge, New Jersey
- +4 more
Dec 1, 2022
Hodgkin's Disease Trial in Baltimore (I-131 Tositumomab therapeutic regimen)
Completed
- Hodgkin's Disease
- I-131 Tositumomab therapeutic regimen
-
Baltimore, MarylandJohns Hopkins Medical Institutions
Jul 31, 2018
Lymphoma, Follicular Trial in United States (Bendamustine, Rituximab, Y-90 ibritumomab)
Lymphoid Leukemia in Remission, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia Trial in Seattle
Completed
- Lymphoid Leukemia in Remission
- +6 more
- Tositumomab and Iodine I 131 Tositumomab
-
Seattle, WashingtonFred Hutchinson Cancer Research Center/University of Washington
Oct 10, 2017
Lymphoma Trial in Stanford (Bexxar, Acetaminophen, Diphenhydramine)
Completed
- Lymphoma
- Bexxar
- +3 more
-
Stanford, CaliforniaStanford University School of Medicine
Feb 28, 2017
Lymphoma, Non-Hodgkin Trial in Stanford (Bexxar (tositumomab), External beam radiotherapy (XRT), Potassium Iodide (KI))
Terminated
- Lymphoma, Non-Hodgkin
- Bexxar (tositumomab)
- +2 more
-
Stanford, CaliforniaStanford University School of Medicine
Feb 9, 2017
Lymphoma, Non-Hodgkin Trial (Iodine-131 Anti-B1 Antibody)
Completed
- Lymphoma, Non-Hodgkin
- Iodine-131 Anti-B1 Antibody
- (no location specified)
Jul 24, 2017
Lymphoma, B-Cell Trial in Durham (cyclophosphamide, etoposide, rituximab)
Completed
- Lymphoma, B-Cell
- cyclophosphamide
- +5 more
-
Durham, North CarolinaDuke University Medical Center
Apr 19, 2017
Lymphoma, Non-Hodgkin Trial in Walla Walla, Pierre-Benite Cedex, Manchester (Tositumomab and Iodine I 131 Tositumomab,
Completed
- Lymphoma, Non-Hodgkin
- Tositumomab and Iodine I 131 Tositumomab
- Rituximab
-
Walla Walla, Washington
- +2 more
Nov 18, 2016
Follicular Lymphoma Trial in Ann Arbor (Bexxar, Low Dose Methotrexate)
Terminated
- Follicular Lymphoma
- Bexxar
- Low Dose Methotrexate
-
Ann Arbor, MichiganUniversity of Michigan
Dec 1, 2016
Lymphoma, Non-Hodgkin Trial (Iodine I 131 Tositumomab Therapeutic Regimen)
Completed
- Lymphoma, Non-Hodgkin
- Iodine I 131 Tositumomab Therapeutic Regimen
- (no location specified)
Nov 18, 2016
Lymphoma, Mantle-Cell Trial (Tositumomab and Iodine I 131 Tositumomab followed by CHOP)
Completed
- Lymphoma, Mantle-Cell
- Tositumomab and Iodine I 131 Tositumomab followed by CHOP
- (no location specified)
Nov 19, 2019
Lymphoma, Non-Hodgkin Trial (tositumomab and iodine I-131 tositumomab)
Completed
- Lymphoma, Non-Hodgkin
- tositumomab and iodine I-131 tositumomab
- (no location specified)
Nov 18, 2016
B-cell Lymphoma, Non-Hodgkin's Lymphoma Trial in Philadelphia (Bexxar)
Completed
- B-cell Lymphoma
- Non-Hodgkin's Lymphoma
- Bexxar
-
Philadelphia, PennsylvaniaAbramson Cancer Center, University of Pennsylvania
Aug 15, 2016
Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine
Completed
- Lymphoma, Non-Hodgkin
- (no location specified)
Jan 28, 2016
Lymphoma, Non-Hodgkin Trial (Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and
Completed
- Lymphoma, Non-Hodgkin
- Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)
- (no location specified)
Aug 1, 2017
Low-Grade Non-Hodgkin's Lymphoma Previously Treated With
Completed
- Lymphoma, Non-Hodgkin
- (no location specified)
Nov 9, 2015
Lymphoma, Non-Hodgkin Trial (Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab)
Completed
- Lymphoma, Non-Hodgkin
- Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab
- (no location specified)
Oct 28, 2016
Lymphoma, Non-Hodgkin Trial (Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody))
Completed
- Lymphoma, Non-Hodgkin
- Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
- (no location specified)
Nov 23, 2016
Lymphoma, Non-Hodgkin Trial (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab))
Completed
- Lymphoma, Non-Hodgkin
- Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
- (no location specified)
Oct 11, 2016
Lymphoma, Non-Hodgkin Trial (Tositumomab and Iodine I 131 Tositumomab)
Completed
- Lymphoma, Non-Hodgkin
- Tositumomab and Iodine I 131 Tositumomab
- (no location specified)
Oct 28, 2016
Lymphoma, Non-Hodgkin Trial (cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I
Completed
- Lymphoma, Non-Hodgkin
- cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.
- (no location specified)
Nov 21, 2016